JP5466012B2 - 抗菌性キノリン誘導体 - Google Patents

抗菌性キノリン誘導体 Download PDF

Info

Publication number
JP5466012B2
JP5466012B2 JP2009539739A JP2009539739A JP5466012B2 JP 5466012 B2 JP5466012 B2 JP 5466012B2 JP 2009539739 A JP2009539739 A JP 2009539739A JP 2009539739 A JP2009539739 A JP 2009539739A JP 5466012 B2 JP5466012 B2 JP 5466012B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
het
formula
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009539739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511669A5 (enExample
JP2010511669A (ja
Inventor
ギルモン，ジエローム・エミル・ジヨルジユ
ドランジユ，イスメ
モツト，マガリ・マドレーヌ・シモヌ
アンドリース，ケンラート・ヨゼフ・ロデビーク・マルセル
コウル，アニル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5466012(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2010511669A publication Critical patent/JP2010511669A/ja
Publication of JP2010511669A5 publication Critical patent/JP2010511669A5/ja
Application granted granted Critical
Publication of JP5466012B2 publication Critical patent/JP5466012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2009539739A 2006-12-06 2007-12-04 抗菌性キノリン誘導体 Active JP5466012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125510.5 2006-12-06
EP06125510 2006-12-06
PCT/EP2007/063314 WO2008068268A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (3)

Publication Number Publication Date
JP2010511669A JP2010511669A (ja) 2010-04-15
JP2010511669A5 JP2010511669A5 (enExample) 2010-11-18
JP5466012B2 true JP5466012B2 (ja) 2014-04-09

Family

ID=37909392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539739A Active JP5466012B2 (ja) 2006-12-06 2007-12-04 抗菌性キノリン誘導体

Country Status (31)

Country Link
US (1) US8293732B2 (enExample)
EP (1) EP2099760B1 (enExample)
JP (1) JP5466012B2 (enExample)
KR (3) KR20170003741A (enExample)
CN (1) CN101547905B (enExample)
AP (1) AP2670A (enExample)
AR (1) AR064147A1 (enExample)
BR (1) BRPI0719939B8 (enExample)
CA (1) CA2668517C (enExample)
CL (1) CL2007003515A1 (enExample)
CY (1) CY1114384T1 (enExample)
DK (1) DK2099760T3 (enExample)
EA (1) EA022344B1 (enExample)
ES (1) ES2407824T3 (enExample)
HR (1) HRP20130372T1 (enExample)
IL (2) IL199078A (enExample)
JO (1) JO2970B1 (enExample)
ME (1) ME01521B (enExample)
MX (1) MX2009005979A (enExample)
MY (1) MY150411A (enExample)
NO (1) NO342095B1 (enExample)
NZ (1) NZ577128A (enExample)
PL (1) PL2099760T3 (enExample)
PT (1) PT2099760E (enExample)
RS (1) RS52753B (enExample)
SG (1) SG10201405650SA (enExample)
SI (1) SI2099760T1 (enExample)
TW (1) TWI396536B (enExample)
UA (1) UA101306C2 (enExample)
WO (1) WO2008068268A1 (enExample)
ZA (1) ZA200903946B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US10508097B2 (en) * 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CN101070304B (zh) * 2002-07-25 2011-10-26 詹森药业有限公司 喹啉衍生物及其作为分枝杆菌抑制剂的应用
CA2553266C (en) 2004-01-23 2013-03-12 Janssen Pharmaceutica N.V. Substituted quinolines and their use as mycobacterial inhibitors
NZ547615A (en) 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Quinoline derivatives and use thereof as mycobacterial inhibitors
MXPA06008596A (es) 2004-01-29 2006-08-28 Janssen Pharmaceutica Nv Derivados de quinolina para uso como inhibidores micobacterianos.
DE602005005810T2 (de) * 2004-05-28 2009-04-09 Janssen Pharmaceutica N.V. Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
CN101065397B (zh) 2004-09-28 2015-10-21 詹森药业有限公司 一种细菌atp合酶的结合结构域
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
LT1898909T (lt) 2005-06-28 2017-02-10 Janssen Pharmaceutica Nv Chinolino dariniai kaip antibakteriniai agentai
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives

Also Published As

Publication number Publication date
CN101547905B (zh) 2015-01-28
WO2008068268A1 (en) 2008-06-12
KR20150126737A (ko) 2015-11-12
PL2099760T3 (pl) 2013-07-31
CL2007003515A1 (es) 2008-07-11
AP2670A (en) 2013-05-15
SG10201405650SA (en) 2014-11-27
NO20092536L (no) 2009-08-24
KR20170003741A (ko) 2017-01-09
EA022344B1 (ru) 2015-12-30
ME01521B (me) 2014-04-20
MX2009005979A (es) 2009-06-16
BRPI0719939B8 (pt) 2021-05-25
AR064147A1 (es) 2009-03-18
PT2099760E (pt) 2013-05-06
EP2099760A1 (en) 2009-09-16
CY1114384T1 (el) 2016-08-31
CA2668517C (en) 2016-01-12
KR20090090339A (ko) 2009-08-25
BRPI0719939B1 (pt) 2020-11-17
NZ577128A (en) 2012-01-12
JO2970B1 (en) 2016-03-15
CN101547905A (zh) 2009-09-30
IL241548A0 (en) 2015-11-30
EP2099760B1 (en) 2013-02-20
HRP20130372T1 (en) 2013-05-31
HK1137433A1 (en) 2010-07-30
US20100029679A1 (en) 2010-02-04
TWI396536B (zh) 2013-05-21
KR101574642B1 (ko) 2015-12-04
CA2668517A1 (en) 2008-06-12
AU2007328888A1 (en) 2008-06-12
ES2407824T3 (es) 2013-06-14
UA101306C2 (en) 2013-03-25
NO342095B1 (no) 2018-03-19
ZA200903946B (en) 2010-08-25
JP2010511669A (ja) 2010-04-15
EA200970536A1 (ru) 2009-10-30
MY150411A (en) 2014-01-15
DK2099760T3 (da) 2013-05-13
BRPI0719939A2 (pt) 2014-03-11
IL241548B (en) 2018-03-29
TW200838530A (en) 2008-10-01
US8293732B2 (en) 2012-10-23
RS52753B (sr) 2013-08-30
KR101908350B1 (ko) 2018-10-16
AP2009004871A0 (en) 2009-06-30
SI2099760T1 (sl) 2013-06-28
IL199078A (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP5466011B2 (ja) 抗菌性キノリン誘導体
JP5356244B2 (ja) 抗菌性キノリン誘導体
JP5356246B2 (ja) 抗菌性キノリン誘導体
JP5466012B2 (ja) 抗菌性キノリン誘導体
JP5356245B2 (ja) 抗菌性キノリン誘導体
JP5466013B2 (ja) 抗菌性キノリン誘導体
CA2612619C (en) Quinoline derivatives as antibacterial agents
AU2007328888B2 (en) Antibacterial quinoline derivatives
HK1137433B (en) Antibacterial quinoline derivatives
HK1124232A1 (zh) 作为抗菌剂的喹啉衍生物
HK1124232B (en) Quinoline derivatives as antibacterial agents
HK1208437B (zh) 抗菌的喹啉衍生物
EA040841B1 (ru) Антибактериальные производные хинолина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130321

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131025

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140123

R150 Certificate of patent or registration of utility model

Ref document number: 5466012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250